ANTIVIRAL THERAPY FOR HERPES SIMPLEX VIRUS ENCEPHALITIS: SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i8.1818Keywords:
Acyclovir, Antiviral therapy, Encephalitis, Herpes simplex virus, ValacyclovirAbstract
Introduction: Without regard to treatment, herpes simplex encephalitis is detrimental. Neonatal encephalitis caused by HSV-2 affects the brain more extensively, resulting in more neurologic complications. Viral variables and host immune responses determine virulence and invasiveness in adults. In order to maintain latency, it is necessary to inhibit viral lyticphase genes and modify innate and adaptive immune responses to thwart host cellular defenses.
The aim: This article explore effectiveness and safety antiviral therapy for herpes simplex virus encephalitis.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 67 articles, whereas the results of our search on SagePub brought up 53 articles. The results of the search conducted for the last year of 2010 yielded a total 11 articles for PubMed and 3 articles for SagePub. In the end, we compiled a total of 8 papers, 7 of which came from PubMed and one of which came from SagePub. We included two research that met the criteria.
Conclusion: The standard treatment of HSV-1 encephalitis is IV acyclovir, as PO acyclovir and valacyclovir require multiple doses per day.
References
Clebak KT, Malone MA. Skin Infections. Prim Care. 2018 Sep;45(3):433–54.
Widener RW, Whitley RJ. Herpes simplex virus. In: Handbook of clinical neurology. Elsevier; 2014. p. 251–63.
Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9):760–72.
Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herpes simplex virus infections. J Neurovirol. 2013;19:328–45.
Whitley R, Baines J. Clinical management of herpes simplex virus infections: past, present, and future. F1000Research. 2018;7.
Gnann JW, Whitley RJ. Herpes simplex encephalitis: an update. Curr Infect Dis Rep. 2017;19:1–12.
James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315.
Kennedy PGE, Steiner I. Recent issues in herpes simplex encephalitis. J Neurovirol. 2013;19:346–50.
Safain MG, Roguski M, Kryzanski JT, Weller SJ. A review of the combined medical and surgical management in patients with herpes simplex encephalitis. Clin Neurol Neurosurg. 2015;128:10–6.
Gnann Jr JW, Sköldenberg B, Hart J, Aurelius E, Schliamser S, Studahl M, et al. Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy. Clin Infect Dis. 2015;61(5):683–91.
Alsweed A, Alsuhibani M, Casanova J-L, Al-Hajjar S. Approach to recurrent herpes simplex encephalitis in children. Int J Pediatr Adolesc Med. 2018;5(2):35–8.
Pouplin T, Pouplin JN, Van Toi P, Lindegardh N, Rogier van Doorn H, Hien TT, et al. Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother. 2011 Jul;55(7):3624–6.
Bradshaw MJ, Venkatesan A. Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management. Neurother J Am Soc Exp Neurother. 2016 Jul;13(3):493–508.
Rabinstein AA. Herpes Virus Encephalitis in Adults: Current Knowledge and Old Myths. Neurol Clin. 2017 Nov;35(4):695–705.
McCray E, Atkinson T, Kearney M, Walker E, Savaliya V. A Review of the Treatment of Herpes Simplex Virus-1 Encephalitis in Six Immunocompetent Patients. Cureus. 2022 Apr;14(4):e24129.
Stahl JP, Mailles A. Herpes simplex virus encephalitis update. Curr Opin Infect Dis. 2019 Jun;32(3):239–43.
Kiyani M, Liu B, Charalambous LT, Adil SM, Hodges SE, Yang S, et al. The longitudinal health economic impact of viral encephalitis in the United States. J Med Microbiol. 2020 Feb;69(2):270–9.
Stránská R, Schuurman R, Nienhuis E, Goedegebuure IW, Polman M, Weel JF, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2005 Jan;32(1):7–18.
Hassan STS, Masarčíková R, Berchová K. Bioactive natural products with anti-herpes simplex virus properties. J Pharm Pharmacol. 2015;67(10):1325–36.
Poole CL, James SH. Antiviral therapies for herpesviruses: current agents and new directions. Clin Ther. 2018;40(8):1282–98.
Álvarez DM, Castillo E, Duarte LF, Arriagada J, Corrales N, Farías MA, et al. Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection [Internet] Vol. 11, Frontiers in Microbiology. 2020. Available from:
https://www.frontiersin.org/articles/10.3389/fmicb.2020.00139
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
